We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Amgen Inc.
Health Care · Biotechnology
Established biotech cashflow ($33B+ revenue run-rate) wrapped around a binary obesity catalyst. Repatha + Prolia + Tezspire growing double-digits offset Enbrel biosimilar erosion. MariTide Phase 3 readouts in obesity/T2D are the structural re-rate path - monthly dosing vs weekly $LLY/$NVO injectables is the differentiated wedge.
- MariTide Phase 3 OBESITY-1/2 readouts 2026-2027; monthly dosing = adherence wedge vs $LLY $NVO weekly
- Repatha trajectory toward $5B+; Tezspire (with $AZN) ramping in severe asthma
- Horizon rare-disease portfolio (Tepezza, Krystexxa) adds non-GLP-1 cashflow leg
- ~$33B revenue run-rate funds R&D + ~3% dividend yield
- Enbrel faces accelerating biosimilar erosion post-2029 IRA negotiation
- Horizon deal added ~$28B net debt; deleveraging gates capital returns
- MariTide Phase 2 GI tolerability signals; Phase 3 binary against $LLY orforglipron oral
- Prolia loses exclusivity 2025-2026; biosimilars already filed
Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.
No major news in the last 7 days for AMGN - only listicles and opinion pieces, which we filter out by default. See everything anyway.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.